{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:19Z","timestamp":1791994579010,"version":"4.4.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to investigate the clinical features of biologics-induced bullous pemphigoid (BP) and the therapeutic effects of those agents for BP, exploring the underlying pathophysiological mechanisms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched PubMed, Web of Science, and Elsevier for studies involving pemphigoid patients treated with or induced by identical biologics published in English from January 2009 to April 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventeen cases of drug-induced BP associated with anti-tumor necrosis factor (aTNF)-\u03b1 therapies, one with interleukin (IL)-17 inhibitors, and seven with IL-12\/IL-23 or IL-23 inhibitors were enrolled. Time to cutaneous toxicity varied among different types of agents, and the characteristics of clinical examinations were similar to idiopathic BP. Discontinuation of the culprit drugs and initiation of topical or systemic corticosteroids were adequate in most cases. Several monoclonal antibodies above have also been reported for the treatment of refractory or recurrent BP, especially concurrent with psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Biologics for immune-related diseases, including TNF-\u03b1, IL-17, and IL-12\/IL-23 or IL-23 inhibitors, can both induce and treat BP, which might be associated with a helper T cells Th1\/Th2 imbalance, complicated inflammatory networks, and a specific individual microenvironment, suggestive of a new perspective on the therapeutic algorithms of BP. There have been numerous reports about biologics inducing or treating BP. We have taken note of this phenomenon and focused on biologics with both pathogenetic and therapeutic effects on BP. Our review summarized the clinical characteristics of associated cases, trying to figure out the underlying mechanisms of this paradoxical phenomenon and to provide an integrated perspective and new therapeutic alternatives for BP.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1050373","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T15:26:52Z","timestamp":1672932412000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics"],"prefix":"10.3389","volume":"13","author":[{"given":"Jie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Hang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Gang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"Bras Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: Trigger and predisposing factors","volume":"10","author":"Moro","year":"2020","journal-title":"Biomolecules"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with pd-1 and pd-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588582","article-title":"Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers","volume":"11","author":"Sadik","year":"2020","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by tnf-targeted therapies","volume":"22","author":"Ramos-Casals","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2089331","article-title":"Bullous pemphigoid induced by biologic drugs in psoriasis: A systematic review","volume":"33","author":"Husein-ElAhmed","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4078\/jkra.2010.17.4.422","article-title":"A case of bullous pemphigoid arising after infliximab therapy in a patient with rheumatoid arthritis","volume":"17","author":"Park","year":"2010","journal-title":"J Korean Rheum Assoc"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.11.018","article-title":"Haha antibodies \u2013 not such a funny story","volume":"8","author":"Hall","year":"2014","journal-title":"J Crohns Colitis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-014-1924-9","article-title":"Bullous pemphigoid occurring under anti-tumor necrosis factor-alpha therapy","volume":"29","author":"Ricci","year":"2014","journal-title":"Int J Colorectal Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2018.3439","article-title":"Infliximab-induced bullous pemphigoid and anti-desmoglein 3 and anti-Bp180 autoantibodies in a patient with ulcerative colitis","volume":"29","author":"Kozaru","year":"2019","journal-title":"Eur J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.03204.x","article-title":"Development of bullous pemphigoid during treatment of psoriasis with adalimumab","volume":"34","author":"Stausb\u00f8l-Gr\u00f8n","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5152\/tjr.2010.31","article-title":"A case with anti tnf- alpha induced bullous pemhigoid","volume":"25","author":"Altindag","year":"2010","journal-title":"Turkish J Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.03.008","article-title":"Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis","volume":"3","author":"Wessman","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000489163","article-title":"Bullous pemphigoid associated with adalimumab therapy in a patient with ulcerative colitis","volume":"10","author":"Hoffmann","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_53_19","article-title":"Simultaneous bullous pemphigoid and vitiligo associated with adalimumab therapy in a patient with psoriasis vulgaris","volume":"11","author":"Tirado-S\u00e1nchez","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4646-20","article-title":"Drug-induced bullous pemphigoid and lupus erythematosus occurring under anti-Tnf-\u03b1 and il-6 therapy in a patient with rheumatoid arthritis","volume":"59","author":"Yoshikawa","year":"2020","journal-title":"Intern Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13466","article-title":"Bullous pemphigoid in a young Male during treatment with adalimumab","volume":"62","author":"van Ammers","year":"2021","journal-title":"Australas J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15770","article-title":"Case of bullous pemphigoid under treatment with adalimumab for hidradenitis suppurativa","volume":"48","author":"Sugaya","year":"2021","journal-title":"J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_794_19","article-title":"Superimposed effects of adalimumab and linagliptin on the development of bullous pemphigoid in a psoriatic patient: A case report","volume":"66","author":"Yamada","year":"2021","journal-title":"Indian J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000318008","article-title":"Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: Two case reports","volume":"221","author":"Boussemart","year":"2010","journal-title":"Dermatology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000243805","article-title":"Bullous pemphigoid during long-term tnf-alpha blocker therapy","volume":"219","author":"Bordignon","year":"2009","journal-title":"Dermatology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2011.04102.x","article-title":"Drug-induced bullous pemphigoid: Cases triggered by intravenous iodine and etanercept","volume":"36","author":"Kluk","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2015.12.006","article-title":"Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient","volume":"2","author":"Wilmer","year":"2016","journal-title":"JAAD Case Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2012.01659.x","article-title":"Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept","volume":"40","author":"Nin","year":"2013","journal-title":"J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1684\/ejd.2010.0970","article-title":"Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept","volume":"20","author":"Cusano","year":"2010","journal-title":"Eur J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.055","article-title":"Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept","volume":"54","author":"Yamauchi","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14002","article-title":"A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis","volume":"31","author":"Loget","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16189","article-title":"Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis","volume":"49","author":"Lu","year":"2022","journal-title":"J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13803","article-title":"Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: A case report","volume":"63","author":"Yun","year":"2022","journal-title":"Australas J Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14291_g","article-title":"Adjuvante therapie mit secukinumab induziert langzeitremission bei einer patientin mit schwerem bull\u00f6sen pemphigoid","volume":"18","author":"Holtsche","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.11.1457","article-title":"Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients","volume":"142","author":"Canizares","year":"2006","journal-title":"Arch Dermatol"},{"key":"B32","first-page":"68","article-title":"Recalcitrant cicatricial pemphigoid treated with the anti-Tnf-Alpha agent etanercept","volume":"9","author":"Kennedy","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.10.1268","article-title":"Successful treatment of mucous membrane pemphigoid with infliximab","volume":"142","author":"Heffernan","year":"2006","journal-title":"Arch Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12163","article-title":"A successful treatment with ustekinumab in a case of antilaminin-Gamma1 pemphigoid associated with psoriasis","volume":"168","author":"Majima","year":"2013","journal-title":"Br J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01506","article-title":"New insights into the pathogenesis of bullous pemphigoid: 2019 update","volume":"10","author":"Genovese","year":"2019","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: A review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01752","article-title":"Bp180 is critical in the autoimmunity of bullous pemphigoid","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"key":"B39","article-title":"Cytokines and bullous pemphigoid","volume":"10","author":"D'Auria","year":"1999","journal-title":"Eur Cytokine Netw"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02169.x","article-title":"Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: Relationships with disease intensity","volume":"138","author":"Ameglio","year":"1998","journal-title":"Br J Dermatol"},{"key":"B41","article-title":"Bullous pemphigoid and pemphigus vulgaris: Correlated behaviour of serum vegf, Se-selectin and tnf-alpha levels","volume":"11","author":"Ameglio","year":"1997","journal-title":"J Biol Regul Homeost Agents"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.7.4840","article-title":"Generation of Th1 and Th2 chemokines by human eosinophils: Evidence for a critical role of tnf-alpha","volume":"179","author":"Liu","year":"2007","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102661","article-title":"The role of T cells in pemphigus vulgaris and bullous pemphigoid","volume":"19","author":"Fang","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.03.1515","article-title":"Identification of immunodominant Th2-cell epitopes in Chinese patients with bullous pemphigoid","volume":"138","author":"Zhang","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15207","article-title":"Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature","volume":"35","author":"Burlando","year":"2022","journal-title":"Dermatol Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2018-001849","article-title":"Bullous pemphigoid induced by ustekinumab: A case report","volume":"28","author":"Marin","year":"2021","journal-title":"Eur J Hosp Pharm"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14199","article-title":"Bullous pemphigoid without detection of autoantibodies in a patient with psoriasis under ustekinumab","volume":"19","author":"Querol-Cisneros","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4274\/turkderm.galenos.2018.11354","article-title":"Ustekinumab associated bullous pemphigoid in a psoriasis patient and a review of the literature","volume":"53","author":"Vural","year":"2019","journal-title":"Turkderm-Turkish Arch Dermatol Venerol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2888","article-title":"Bullous pemphigoid during ustekinumab therapy in a psoriatic patient","volume":"27","author":"Onsun","year":"2017","journal-title":"Eur J Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2015.07.014","article-title":"Bullous pemphigoid during ustekinumab therapy","volume":"1","author":"Le Guern","year":"2015","journal-title":"JAAD Case Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12943","article-title":"Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab","volume":"42","author":"Nakayama","year":"2015","journal-title":"J Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13909","article-title":"Development of bullous pemphigoid during secukinumab treatment for psoriasis","volume":"44","author":"Ho","year":"2017","journal-title":"J Dermatol"},{"key":"B53","article-title":"Lichen planus pemphigoides treated with ustekinumab","volume":"100","author":"Knisley","year":"2017","journal-title":"Cutis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13263","article-title":"Successful treatment of recalcitrant lichen planus pemphigoides with tildrakizumab","volume":"61","author":"Kerkemeyer","year":"2020","journal-title":"Australas J Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/srep18001","article-title":"Integrating longitudinal serum il-17 and il-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome","volume":"5","author":"Pl\u00e9e","year":"2015","journal-title":"Sci Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/bor.0000000000000147","article-title":"Inhibition of interleukin-17, interleukin-23 and the Th17 cell pathway in the treatment of psoriatic arthritis and psoriasis","volume":"27","author":"Mease","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051819","article-title":"Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity","volume":"7","author":"Tsuda","year":"2012","journal-title":"PloS One"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00802.x","article-title":"Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters","volume":"37","author":"Reddy","year":"2010","journal-title":"J Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced il-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1519","article-title":"Th17\/Il23 cytokine gene polymorphisms in bullous pemphigoid","volume":"8","author":"Tabatabaei-Panah","year":"2020","journal-title":"Mol Genet Genomic Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00701","article-title":"Net formation in bullous pemphigoid patients with relapse is modulated by il-17 and il-23 interplay","volume":"10","author":"Giusti","year":"2019","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1737638","article-title":"Off-label dermatologic uses of il-17 inhibitors","volume":"33","author":"Wu","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15295","article-title":"Case of pemphigus foliaceus misdiagnosed as a single condition of erythrodermic psoriasis and modified by brodalumab","volume":"47","author":"Morishima-Koyano","year":"2020","journal-title":"J Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20176481","article-title":"Biologic therapy-induced pemphigus","volume":"92","author":"Hayashida","year":"2017","journal-title":"Bras Dermatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14760","article-title":"Secukinumab decreased circulating anti-Bp180-Nc16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid","volume":"46","author":"Kamata","year":"2019","journal-title":"J Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2797","article-title":"Activation of neutrophils by autocrine il-17a-Il-17rc interactions during fungal infection is regulated by il-6, il-23, ror\u03b3t and dectin-2","volume":"15","author":"Taylor","year":"2014","journal-title":"Nat Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e21770","DOI":"10.7759\/cureus.21770","article-title":"Bullous pemphigoid associated with pembrolizumab therapy for non-Small-Cell lung cancer: A case report","volume":"14","author":"Chatterjee","year":"2022","journal-title":"Cureus"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.5070\/d327955136","article-title":"Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: A case report and review of the literature","volume":"27","author":"Klepper","year":"2021","journal-title":"Dermatol Online J"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000003894","article-title":"Immunotherapy (Cemiplimab)-induced bullous pemphigoid: A possible pitfall in 18f-fdg Pet\/Ct","volume":"47","author":"Gr\u00fcnig","year":"2022","journal-title":"Clin Nucl Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.annder.2021.08.005","article-title":"Updated French guidelines for the therapeutic management of bullous pemphigoid","volume":"149","author":"Castel","year":"2022","journal-title":"Ann Dermatol Venereol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800609","article-title":"Commentary: Efficacy and safety of dupilumab in moderate-to-Severe bullous pemphigoid","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738907","article-title":"Efficacy and safety of dupilumab in moderate-to-Severe bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in Switzerland: A 2-year prospective study","volume":"161","author":"Marazza","year":"2009","journal-title":"Br J Dermatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.03839.x","article-title":"Medication history of a series of patients with bullous pemphigoid from northern Greece - observations and discussion","volume":"48","author":"Patsatsi","year":"2009","journal-title":"Int J Dermatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.V48N9p301","article-title":"Characteristics and management of autoimmune bullous disease in psoriasis patients","volume":"48","author":"Toh","year":"2019","journal-title":"Ann Acad Med Singap"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/cup.14206","article-title":"Concominant bullous pemphigoid and cutaneous crohn disease","volume":"49","author":"Cobb","year":"2022","journal-title":"J Cutan Pathol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00719-7","article-title":"Management of coexisting bullous pemphigoid and psoriasis: A review","volume":"23","author":"Hsieh","year":"2022","journal-title":"Am J Clin Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1050373\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T15:26:56Z","timestamp":1672932416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1050373\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":78,"alternative-id":["10.3389\/fimmu.2022.1050373"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1050373","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"article-number":"1050373"}}